Novartis Raises 2026 Core Operating Profit Guidance
Novartis said it expects 2026 core operating profit to rise, citing solid sales growth and productivity gains, despite third-quarter profit pressure from recent clinical-trial setbacks.
Story updates
06:45:38 AM UTC
SquawkNews
BASEL (dpa-AFX) - Swiss drug major Novartis AG (NVS, NOVN.SW) reported Tuesday sharply lower profit in its third quarter, mainly hurt by an impairment charge and higher expenses, despite growth in net sales.Further, the firm raised fiscal 2026 outlook for core operating income and confirmed sales g…
By Adria CalatayudNovartis raised its full-year earnings guidance, citing solid sales growth and productivity gains, even as recent clinical-trial setbacks hit the Swiss drugmaker's bottom line in the third quarter.The company said Tuesday that it now expects 2026 core operating profit to rise by a…